The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preferred treatment regimens for rare genitourinary (GU) malignancies.
 
Nicholas Simon
No Relationships to Disclose
 
Stephanie Berg
Honoraria - Aptitude Health; MJH Life Sciences
Consulting or Advisory Role - Bristol Meyers Squibb; Eisai; Exelixis; Exelixis; Genzyme; Myovant Sciences; Pfizer; Seattle Genetics/Astellas
 
Alan Tan
Stock and Other Ownership Interests - Adaptimmune; Aprea AB; Bluebird Bio; Editas Medicine; FATE Therapeutics; Fusion Pharmaceuticals; ImmunityBio; Iovance Biotherapeutics; MEI Pharma; natera; RAPT Therapeutics
Honoraria - Bristol Myers Squibb Foundation; EMD Serono; Exelixis; Gilead Sciences; Merck; Myovant Sciences; natera; Seagen
Consulting or Advisory Role - Exelixis; Foundation Medicine; Myovant Sciences
Speakers' Bureau - bristol myers squibb; EMD Serono; Exelixis; Gilead Sciences; Merck; natera
 
Elias Chandran
No Relationships to Disclose
 
Saad Atiq
No Relationships to Disclose
 
Andre Kydd
No Relationships to Disclose
 
Lisa Cordes
No Relationships to Disclose
 
Amir Mortazavi
Consulting or Advisory Role - Targeted Oncology
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Seagen (Inst)
 
Melissa Reimers
Honoraria - Society of Urologic Nurses and Associates (SUNA)
Consulting or Advisory Role - Astellas Pharma; Loxo; Pathos AI, Inc
Research Funding - Amgen (Inst); AstraZeneca (Inst); BMS GmbH & Co. KG (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Genentech (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); ProfoundBio (Inst)
 
Matthew Milowsky
Stock and Other Ownership Interests - Gilead Sciences; Merck; Pfizer
Research Funding - Accuray (Inst); Acrivon Therapeutics (Inst); Alliance for Clinical Trials in Oncology (Inst); Alliance Foundation Trials (Inst); ALX Oncology (Inst); Arvinas (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Flare Therapeutics (Inst); G1 Therapeutics (Inst); Genentech (Inst); Hoosier Cancer Research Network (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OncoC4 (Inst); PCCTC (Inst); Roche (Inst); Seagen (Inst)
Other Relationship - Elsevier; Medscape; Prime Education; Research to Practice
(OPTIONAL) Uncompensated Relationships - G1 Therapeutics; Loxo/Lilly
 
Cora Sternberg
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Foundation Medicine; Genzyme; Gilead Sciences; Immunomedics; IMPAC Medical Systems; Incyte; Janssen Oncology; Medscape; Merck; MSD; Pfizer; Roche; UroToday
Travel, Accommodations, Expenses - Merck
 
Jonathan Rosenberg
Honoraria - Clinical Care Options; MashupMD; Medical Educator Consortium; Medscape; MJH Life Sciences; NCCN/Pfizer; Peerview; Pfizer; Physicans' Education Resource; Research To Practice; Touch Oncology; UpToDate
Consulting or Advisory Role - Aktis Oncology; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Century Therapeutics; EMD Serono; Generate Biomedicines; Gilead Sciences; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer; Roche/Genentech; Samsung Bioepis; Seagen; Tyra Biosciences
Research Funding - Acrivon Therapeutics; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); Lilly; Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Amplification of chromosome 1q23 to predict cancer outcomes (Inst); Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Seagen
(OPTIONAL) Uncompensated Relationships - Alliance for Clinical Trials in Oncology
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Curis; Daiichi Sankyo Europe GmbH; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Andrea Apolo
No Relationships to Disclose